Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$5.92 USD

5.92
91,442

+0.18 (3.14%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $5.94 +0.02 (0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why

by Zacks Equity Research

Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.

Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

by Zacks Equity Research

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer

by Zacks Equity Research

Merck (MRK) partners with Kelun-Biotech to develop seven antibody-drug conjugates targeting cancer indications. Merck will have an exclusive license to develop and commercialize these candidates.

Pfizer's (PFE) Etrasimod Filings Receive Review Acceptance

by Zacks Equity Research

The regulatory filings seek approval for Pfizer's (PFE) etrasimod in UC indication. A final decision in the U.S. is expected in 2023, while the decision in the EU is expected in 2024.

Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug

by Zacks Equity Research

Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

by Zacks Equity Research

Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.

LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China

by Zacks Equity Research

As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.

AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs

by Zacks Equity Research

The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.

Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids

by Zacks Equity Research

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.

Wave Life Sciences (WVE) Up 26% on Collaboration With GSK

by Zacks Equity Research

Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines

by Zacks Equity Research

Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.

Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study

by Zacks Equity Research

Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.

Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy

by Zacks Equity Research

Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.

Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy

by Zacks Equity Research

Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.

Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.

Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag

by Zacks Equity Research

Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.

Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data

by Zacks Equity Research

Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.

New Strong Buy Stocks for November 28th

by Zacks Equity Research

KMDA, SLCA and FTNT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2022.

Kamada (KMDA) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Kamada (KMDA) delivered earnings and revenue surprises of 433.33% and 8.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Science 37 Holdings, Inc. (SNCE) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Science 37 Holdings, Inc. (SNCE) delivered earnings and revenue surprises of 5.88% and 21.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 106.15% and 271.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?